Phase 3 N=20 The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis
Allergic Contact Dermatitis
Primary: Clinical Reaction — 0; 0; 12; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=259 Contact Sensitization Potential of 828 Ointment
Healthy Volunteers
Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants
Phase 2 N=122 Clinical Evaluation of Metal Panel Allergens: Dose Response Study
Dermatitis, Eczematous
Primary: Number of Participants With Patch Test Responses — 0; 105; 16; 0 Participants
Phase 3 N=235 Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy
Contact Dermatitis
Primary: Diagnostic Performance: Concordance Between Investigational Allergen and Reference Allergen at Day 21 — 78.9 percentage of concordant responses
Phase 2 N=12 Study of Apremilast in Atopic or Contact Dermatitis
Atopic Dermatitis · Allergic Contact Dermatitis
Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants
Phase 2 N=48 Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
Contact Dermatitis
Primary: Diagnostic Performance: Optimal Test Allergen Concentration — 38.1; 47.6; 52.4; 30.8 percentage of participants
N/A N=50 Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis
Allergic Contact Dermatitis
Primary: Evaluation of Serum Biomarker Concentrations at the Time of Enrollment (T0) — 14.53; 16.03; 109.1; 110.7 pg/ml
N/A N=68 Human Repeated Insult Patch Test
Dermatitis · Allergy · Contact Allergy
Primary: Erythema at the Patch Test Site is Evaluated for Each Participant — 0.00; 0.59; 0.00 erythema score
Phase 1 N=59 Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
Healthy
Primary: Frequency Distribution of Skin Irritation Scores — 39; 10; 3; 0 Scores on a scale
Phase 2 N=22 Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis
Dermatitis, Allergic Contact
Primary: Number of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 1 — 5; 9 Participants
Phase 2 N=56 Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study
Contact Dermatitis
Primary: Number of Participants Who Exhibit Positive Responses to Each Allergen Concentration — 4; 0; 0; 2 Participants
Phase 1 N=58 Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream
Photoallergy
Primary: Within-subject Comparison of Dermal Reaction by the Overall Numeric Rating of Erythema and Edema at 5 Defined Test Sites, After Application of MC2-01 Cream, MC2-01…
Phase 2 N=28 Mechlorethamine Induced Contact Dermatitis Avoidance Study
Cutaneous T-cell Lymphoma · Cutaneous T-cell Lymphoma Stage I · Mycosis Fungoides
Primary: Incidence of Moderate to Severe Contact Dermatitis by SCORD Scoring — 16; 11 patients
N/A N=86 HRIPT for Collagen Dressing
Skin Sensitisation
Primary: Skin Sensitization Reaction Using Berger and Bowman Scale — 0; 0; 0; 0 score on a scale
Phase 1 N=59 Cumulative Irritation Potential of 828 Ointment
Healthy Volunteers
Primary: Presence of Cumulative Irritation — 163.0; 109.0; 2073.0 units on a scale
N/A N=80 A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients
Dermatitis, Contact
Primary: Treatment Status (Success/Failure) of Contact Dermatitis (CD) at the Second Follow-up Visit — 93.8; 6.30 Percentage of Participants
Phase 4 N=206 Neo-Synalar Modified 48 Hour Patch Test
Allergy
Primary: Evidence of Pre-Existing Sensitization by Use of the Erythemal Scoring Scale (ESS) — 0 percentage of patients w allergic rxn
Phase 1 N=61 A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers
Healthy
Primary: Observed Photoallergy (Photosensitization): Number of Skin Sites by Maximum Total Irritation Score — 10; 3; 1; 0 Number of affected skin sites
N/A N=36 Patch Test of Benzalkonium Chloride Disinfectant Spray
Wound Healing
Primary: Proportion of Participants With Skin Irritation Scores at 24 Hours — 75.0; 91.7; 94.4; 94.4 Percentage of participants
Phase 4 N=20 A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis
Hand Dermatitis
Primary: Primary Outcome Measure for Efficacy (IGA) — 2.33; 2.20; 2.43; 2 score on a scale
N/A N=81 SPT for Sensitization of Collagen Dressing
Allergy Skin · Allergic Skin Reaction
Primary: Wheal Measurement — 0; 7.91; 0.32 mm
N/A N=36 To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facial Product in Healthy Participants
Skin Care
Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 2 — 0; 0 Score on scale
N/A N=43 14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin
Cumulative Irritation
Primary: Number of Subjects That Showed no Significant Irritation — 0 participants
N/A N=1,260 A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019
N/A N=280 To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Facial Products
Skin Care
Primary: Percentage of Participants With Potential Sensitisation Reactions as Assessed by Dermatologist on Day 40 — 2; 1; 1; 0 Number of participants
N/A N=118 Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100
Allergic Sensitization
Primary: Number of Participants That Did Not Have Test Material Induced Clinically Significant Dermal Irritation — 110 Participants
N/A N=43 14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon
Dermal Irritation
Primary: Number of Subjects That Showed Erythema Based on 5 Point Scoring Scale — 0 Participants
N/A N=9 Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis · Eczema
Primary: SCORAD Change Score — 33.34 Change Score
Phase 2 N=22 Clinical Evaluation of Lyral® Dose Response Study
Contact Dermatitis
Primary: Number of Participants With Positive Patch Test Responses — 14; 12; 11; 0 participants
Phase 3 N=202 Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Mean Ocular Itching at Onset of Action — 0.4; 1.9; 0.4; 0.6 Units on a scale